<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zucapsaicin (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zucapsaicin (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zucapsaicin (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="16821" href="/d/html/16821.html" rel="external">see "Zucapsaicin (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871395"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zuacta [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13265102"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Topical;</li>
<li>
                        Topical Skin Product;</li>
<li>
                        Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F13265140"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4badd17d-fd07-41cf-a078-cfd0949a8653">Pain relief in osteoarthritis of knee</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;display:inline">
<b>Pain relief in osteoarthritis of knee:</b> Topical: Apply a pea-sized amount to 3 locations around affected knee 3 times daily; allow at least 4 hours between applications (maximum: 3 applications/day). Therapy should be limited to ≤3 months.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>: Apply the dose as soon as possible, but not within four hours of the next dose.</p></div>
<div class="block dora drugH1Div" id="F50989957"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, dosage adjustment does not appear to be necessary since there is no systemic absorption following topical administration of zucapsaicin.</p></div>
<div class="block doha drugH1Div" id="F50987275"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, dosage adjustment does not appear to be necessary since there is no systemic absorption following topical administration of zucapsaicin.</p></div>
<div class="block doe drugH1Div" id="F13265141"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F13265122"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Application-site burning (35%; including severe burning skin [6% to 10%])</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of skin (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (4%; including application-site edema [&lt;1%], application-site erythema [&lt;1%], application-site irritation [1%], application-site pain [&lt;1%], application-site pruritus [1%], application-site rash [1%], local dryness of skin [&lt;1%], sensation of cold [&lt;1%]), localized numbness (3%), localized warm feeling (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (2%), sneezing (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin blister, skin discoloration, skin photosensitivity, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, nasal congestion, nasal mucosa irritation, throat irritation</p></div>
<div class="block coi drugH1Div" id="F13265106"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to zucapsaicin or any component of the formulation; application to broken or irritated skin or areas with a compromised skin barrier</p></div>
<div class="block war drugH1Div" id="F13265107"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cough: May induce cough; do not apply to the face. Wash hands thoroughly after each application.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only. Avoid contact with eyes, lips, genital areas, broken or irritated skin or on areas with a compromised skin barrier Avoid application of other topical products to zucapsaicin treated areas. Do not use under occlusive dressings. Avoid hot baths or showers just prior to or right after application to avoid a possible burning sensation. Safety and efficacy have only been evaluated in the treatment of osteoarthritis of the knee; has not been evaluated and is not recommended for use in other arthritic, inflammatory, or painful musculoskeletal conditions, in severe neurological or vascular disease, and/or in osteoarthritis of the knee secondary to other pathological processes</p></div>
<div class="block prod-avail drugH1Div" id="F13265158"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040757"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block dinfoc drugH1Div" id="F52871396"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zuacta: 0.075% ([DSC]) [contains benzyl alcohol, cetyl alcohol, peg-100 stearate]</p></div>
<div class="block adm drugH1Div" id="F13265142"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Topical: For external use only on intact skin; do not apply to broken or irritated skin. Gently rub in a circular motion into affected knee until no residue is left on skin. Do not cover treated area with occlusive dressing. Wash hands thoroughly after application. Avoid taking a hot bath or shower immediately before or after administration (may cause burning sensation). Avoid contact with eyes, lips, and genital area. Avoid concomitant application of other topical medications to treated areas.</p></div>
<div class="block use drugH1Div" id="F13265103"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarthritis of the knee</b>: In conjunction with an oral NSAID or COX-2 inhibitor for short-term (≤3 months) treatment of severe pain associated with osteoarthritis of the knee that is not controlled by NSAID or COX-2 inhibitor monotherapy</p></div>
<div class="block cyt drugH1Div" id="F13300242"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F13271221"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13265104"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. Zucapsaicin is not absorbed systemically following topical administration. Use during pregnancy is not expected to result in significant exposure to the fetus.</p></div>
<div class="block brc drugH1Div" id="F18881621"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if zucapsaicin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering zucapsaicin to nursing women.</p></div>
<div class="block pha drugH1Div" id="F13265130"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Actions are thought to be similar to other capsaicinoids, such as capsaicin, which is a transient receptor potential vanilloid 1 receptor (TRPV1) agonist, that activates TRPV1 ligand-gated cation channels on nociceptive nerve fibers, resulting in depolarization, initiation of action potential, and pain signal transmission to the spinal cord; capsaicin exposure results in subsequent desensitization of the sensory axons, depletion of proinflammatory neuropeptides (eg, calcitonin gene-related peptide, substance P) and inhibition of pain transmission initiation. In arthritis, capsaicin induces release of substance P, the principal chemomediator of pain impulses from the periphery to the CNS, from peripheral sensory neurons; after repeated application, capsaicin depletes the neuron of substance P and prevents reaccumulation. The functional link between substance P and the capsaicin receptor, TRPV1, is not well understood.</p></div>
<div class="block phk drugH1Div" id="F13265132"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Systemic absorption is negligible</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Zuacta (zucapsaicin cream 0.075%) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; November 2010</div>
</li></ol></div><div id="topicVersionRevision">Topic 16820 Version 50.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
